McCollum Christoferson Group LLC Decreases Holdings in Clorox Co (NYSE:CLX)

McCollum Christoferson Group LLC decreased its position in shares of Clorox Co (NYSE:CLX) by 2.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,265 shares of the company’s stock after selling 355 shares during the quarter. McCollum Christoferson Group LLC’s holdings in Clorox were worth $2,449,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the company. Athena Capital Advisors LLC bought a new stake in shares of Clorox during the 4th quarter worth $25,000. Meeder Asset Management Inc. bought a new stake in shares of Clorox during the 4th quarter worth $26,000. Capital Financial Planning LLC bought a new stake in shares of Clorox during the 4th quarter worth $32,000. City Holding Co. raised its stake in shares of Clorox by 150.0% during the 4th quarter. City Holding Co. now owns 250 shares of the company’s stock worth $39,000 after purchasing an additional 150 shares during the period. Finally, G&S Capital LLC raised its stake in shares of Clorox by 46.4% during the 4th quarter. G&S Capital LLC now owns 262 shares of the company’s stock worth $40,000 after purchasing an additional 83 shares during the period. Institutional investors own 76.98% of the company’s stock.

CLX has been the topic of a number of research reports. Zacks Investment Research cut Clorox from a “hold” rating to a “sell” rating in a research note on Tuesday, April 9th. Deutsche Bank upgraded Clorox from a “sell” rating to a “hold” rating and set a $139.00 price objective on the stock in a research note on Thursday. Wells Fargo & Co lowered their price objective on Clorox from $157.00 to $153.00 and set a “market perform” rating on the stock in a research note on Thursday. Citigroup lowered their price objective on Clorox from $171.00 to $160.00 and set a “neutral” rating on the stock in a research note on Thursday. Finally, BMO Capital Markets set a $168.00 price objective on Clorox and gave the company a “buy” rating in a research note on Thursday. Four equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. Clorox currently has a consensus rating of “Hold” and a consensus target price of $149.57.

Shares of CLX opened at $148.18 on Friday. Clorox Co has a twelve month low of $115.74 and a twelve month high of $167.70. The stock has a market cap of $18.99 billion, a PE ratio of 23.67, a P/E/G ratio of 4.15 and a beta of 0.31. The company has a current ratio of 1.15, a quick ratio of 0.66 and a debt-to-equity ratio of 3.08.

Clorox (NYSE:CLX) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $1.44 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.47 by ($0.03). Clorox had a return on equity of 105.97% and a net margin of 12.65%. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the previous year, the firm posted $1.37 EPS. The firm’s revenue for the quarter was up 2.2% compared to the same quarter last year. As a group, sell-side analysts predict that Clorox Co will post 6.3 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Stockholders of record on Wednesday, April 24th will be issued a dividend of $0.96 per share. This represents a $3.84 annualized dividend and a dividend yield of 2.59%. The ex-dividend date is Tuesday, April 23rd. Clorox’s payout ratio is 61.34%.

In other Clorox news, SVP Matthew T. Laszlo sold 10,585 shares of the company’s stock in a transaction that occurred on Wednesday, February 6th. The stock was sold at an average price of $153.89, for a total value of $1,628,925.65. Following the completion of the sale, the senior vice president now owns 17,994 shares of the company’s stock, valued at $2,769,096.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Andrew J. Mowery sold 5,340 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $156.44, for a total value of $835,389.60. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This article was posted by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.baseballdailydigest.com/news/2019/05/04/mccollum-christoferson-group-llc-lowers-stake-in-clorox-co-clx.html.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Read More: Outstanding Shares and The Effect on Share Price

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.